Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Citius PharmaceuticalsCTXR +6.28%25 Market Cap is $18.73 Mil as of Aug. 08, 2026. GuruFocus rates CTXR with a GF Score™ of 25/100. The stock has 2 warning signs investors should review. Among 1,423 Biotechnology companies, Citius Pharmaceuticals ranks worse than 77.44% on this metric.
Citius Pharmaceuticals's quarterly market cap
declined
from Sep. 2025 ($22.40 Mil) to Dec. 2025 ($17.39 Mil) but then
increased
from Dec. 2025 ($17.39 Mil) to Mar. 2026 ($20.14 Mil).
Citius Pharmaceuticals's annual market cap
declined
from Sep. 2023 ($108.72 Mil) to Sep. 2024 ($90.70 Mil) and
declined
from Sep. 2024 ($90.70 Mil) to Sep. 2025 ($22.40 Mil).
Enterprise Value is the theoretical takeover price. It is more comprehensive than market capitalization (market cap), which only includes common equity. Enterprise Value is calculated as the market cap plus debt and minority interest and preferred shares, minus total cash and cash equivalents. Citius Pharmaceuticals's Enterprise Value for Today is $22.49 Mil.
Citius Pharmaceuticals (NAS:CTXR) Market Cap Explanation
Market cap is not the real price you pay for a company. If you buy the company and become its owner, you become the owner of the cash the company has, and you also assume the companys debt. The real price you pay is the Enterprise Value.
Warren Buffett uses the ratio of total market cap of all public traded companies over GDP to measure if the market is expensive. As of April 2012, the US total market cap is about $14.7 trillion, while the US GDP is about $15 trillion. The market was modestly overvalued.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Biotechnology subindustry, Citius Pharmaceuticals's Market Cap, along with its competitors' market caps and Market Cap data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Citius Pharmaceuticals Market Cap vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Citius Pharmaceuticals's Market Cap distribution charts can be found below:
* The bar in red indicates where Citius Pharmaceuticals's Market Cap falls into.
Market cap is the short version of market capitalization. It is the total market value to buy the whole company. It is equal to the share price times the number of shares outstanding.
Citius Pharmaceuticals's Market Cap for the fiscal year that ended in Sep. 2025 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Citius Pharmaceuticals (CTXR) has a Market Cap of $18.73 Mil as of Aug. 08, 2026. Market cap equals the total value of a company's shares: price times shares outstanding. View historical data on Citius Pharmaceuticals and its competitors. According to the industry distribution chart, Citius Pharmaceuticals ranks #1102 out of 1423 companies in the Biotechnology industry, placing it in the top 77.4%.
Is Citius Pharmaceuticals' Market Cap too high?
Citius Pharmaceuticals' current Market Cap is $18.73 Mil. The Biotechnology industry median Market Cap is 116.70. Citius Pharmaceuticals' value of $18.73 Mil is 84% below this industry median. Based on the distribution chart, Citius Pharmaceuticals ranks #1102 out of 1423 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, Citius Pharmaceuticals has a GF Score™ of 25/100, reflecting its overall financial health beyond just this single metric.
How does Citius Pharmaceuticals' Market Cap compare to LEXX and HIND?
According to the Biotechnology industry distribution chart, Citius Pharmaceuticals ranks #1102 out of 1423 companies for Market Cap. This places Citius Pharmaceuticals in the lower half of its industry. The industry median Market Cap is 116.70. Citius Pharmaceuticals' value of $18.73 Mil is 84% below this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Market Cap for a Biotechnology company?
The median Market Cap among Biotechnology companies is 116.70, based on 1,423 companies in the industry. Companies in the top quartile (top 25%) have a Market Cap significantly above this median, while those in the bottom quartile fall well below. However, Market Cap should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Citius Pharmaceuticals's current Market Cap of $18.73 Mil is 84% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Market Cap mean?
A high Market Cap can signal that a stock is expensive relative to its fundamentals. Market cap equals the total value of a company's shares: price times shares outstanding. View historical data on Citius Pharmaceuticals and its competitors. For the Biotechnology industry, the median Market Cap is 116.70 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Citius Pharmaceuticals's current Market Cap is $18.73 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Citius Pharmaceuticals stock overvalued right now?
Citius Pharmaceuticals (CTXR) has a current Market Cap of $18.73 Mil. The current Market Cap is $18.73 Mil and 84% below the Biotechnology industry median of 116.70. Citius Pharmaceuticals' overall GF Score™ is 25/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Market Cap calculated?
Market Cap is calculated from a company's financial statements. For Citius Pharmaceuticals (CTXR), the current Market Cap is $18.73 Mil as of Aug. 08, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Citius Pharmaceuticals Inc is a biopharmaceutical company dedicated to the development and commercialization of first-in-class critical care products, with a focus on oncology, anti-infectives in adjunct cancer care and distinct prescription products. It aims to provide therapeutic products that address unmet medical needs yet have a lower development risk than is usually associated with new chemical entities. The company's flagship product candidate is LYMPHIR, an engineered IL-2 diphtheria toxin fusion protein. It operates through a single operating and reportable segment which is focused on developing and commercializing pioneering targeted oncology therapies.
25GF Score
Get the complete analysis for CTXR
Market Cap is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
CTXR has been successfully added to your 
